Femmenessence(TM) (Maca-GO(TM)) Balances Hormonal Fluctuation for Menopause Sufferers...

Mon Jan 14, 2008 9:15am EST

* Reuters is not responsible for the content in this press release.

Femmenessence(TM) (Maca-GO(TM)) Balances Hormonal Fluctuation for Menopause Sufferers with All-Natural Alternative to HRT

SAN FRANCISCO--(Business Wire)--A proprietary high quality formulation of the Peruvian herb Maca
has recently been shown to fight the cause of menopause, by balancing
the body's key hormones with an all-natural, homeostatic approach.

   Natural Health International's (NHI) Maca-GO(TM) or
Femmenessence(TM) is the only scientifically and clinically proven
Maca product on the market that significantly reduces menopausal
symptoms and improves hormone levels.

   "Beating menopause is all about controlling rapid hormonal
fluctuations during peri menopause and reversing the body's reduced
production of all hormones, not just one or two, during post
menopause," said Jan Roberts B. Pharm, Clinical Nutritionist and best
selling author. "And, NHI's Femmenessence(TM) MacaPause product for
post menopause and Femmenessence(TM) MacaLife(TM) for peri menopause
specifically targets the different needs of women at these diverse
stages of menopause."

   The Women's Health Initiative (WHI Study) found that Hormone
Therapy (HT or HRT) can lead to an increased risk of developing
serious health problems such as stroke and breast cancer. Many women
have been seeking a safe, natural alternative to HT since the release
of the WHI findings with limited success.

   While natural alternatives like soy, red clover and black cohosh
may reduce some symptoms, their effects on actual hormone levels have
not been significantly demonstrated. Since reduced hormone levels
after menopause directly relate to a woman's susceptibility to heart
disease, osteoporosis, and cognitive function, many doctors and women
are turning back to hormone therapies in an attempt to avert these
life-threatening conditions.

   Femmenessence(TM) (Maca-GO(TM)) offers women and mainstream
medicine a natural, safe alternative that works. Five years of
published clinical trials and research on Femmenessence(TM) reveal an
84% success rate in reduction of menopausal symptoms (hot flashes,
night sweats, fatigue, mood swings, etc.), increased bone density,
enhanced absorption of iron, calcium and other trace elements, and a
better ability to maintain a healthy weight, optimal cholesterol and
triglyceride levels.

   "Femmenessence(TM) does not introduce synthetic, animal or plant
hormones into the body, rather it works through the body, stimulating
the hypothalamus, pituitary, and adrenal glands to support and balance
the body's own production of key hormones such as FSH, Estrogen and
Progesterone," explained Dr. Henry Meissner, Head of Research and
Development at NHI.

   NHI's three Femmenessence products are designed to help women at
different stages of life: Femmenessence(TM) MacaPause(TM) is designed
to help women deal with the symptoms of post menopause as well as to
reverse the loss of hormone production and support heart, bone and
mental health throughout the second fifty years of life.
Femmenessence(TM) MacaLife(TM) is designed to reduce symptoms
associated with peri menopause and the fluctuation of hormones during
this stage, and Femmenessence(TM) MacaHarmony is for younger women to
support hormone balance, critical for fertility and PMS.

   "Femmenessence(TM) is proving to be the only serious alternative
to hormone therapies, for women looking for a natural alternative,"
stated Roberts

   Natural Health International (NHI) is a global natural products
and wellness company. The company controls the entire process from
seed to shelf with operations in the US, Peru, Australia, New Zealand,
Vanuatu and Asia. NHI provides clinically-proven natural products and
functional foods to address specific health conditions for men and
women. www.femenessence.com

For Natural Health International
Rodney Anderson, 888-668-3661
rodney.anderson@naturalhi.com

Copyright Business Wire 2008
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.